Lupin Limited has informed the Exchange regarding a press release dated February 02, 2026, titled "Lupin and TB Alliance Join Forces to Advance Telacebec for the Treatment of Tuberculosis and Other Mycobacterial Diseases".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has announced a collaboration with TB Alliance, a global non-profit dedicated to TB research, to advance the development of Telacebec, a drug aimed at treating Tuberculosis and other Mycobacterial diseases. The partnership will focus on progressing the clinical development and commercialization pathway for Telacebec. TB Alliance is a recognized global player in tuberculosis drug development, giving the collaboration strong credibility. Lupin strengthens its presence in the infectious diseases and global health space through this tie-up.
Positive for Lupin's long-term pipeline, particularly in anti-infectives and global health. May not move the stock sharply in the short term, but adds strategic value to Lupin's R&D portfolio and could open doors to global public health procurement opportunities.